Multiple Sclerosis (MS) Clinical Trial
Official title:
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
The main aim of the present study is to assess the prevalence, the topography and the
clinical counterpart of cortical lesions in patient included early after the first clinical
episode of multiple sclerosis. A second aim is to assess the direct contribution of cortical
lesions - independent of WM injury - on the diffuse grey matter damage.
Thirty MS patients will be included in the six months after the first clinical episode of
multiple sclerosis for a monocentric transversal MRI study at 7T to assess cortical MS
injury. Clinical (EDSS) and neuropsychological assessments will be performed in the
population the same day of a multi-parametric MRI. MRI protocol is designed to increase the
detection rate of CL using multiple contrasts at high isotropic resolution (600µm3) on a
whole brain exploration. Thus, MRI acquisition will include MP2RAGE, T2*, FLAIR and DIR as
previously published but also recent MRI technique like FLAWS, focusing on the grey matter by
attenuating the white matter and CSF signal. Finally, QSM sequences will be performed. QSM
measures tissue magnetic susceptibility mostly influenced by iron, myelin and calcium content
in the brain. Due to physical properties of the technique (bipolarity), we suppose that high
resolution QSM will be more sensitive that previous used sequences to depict cortical
lesions. Using this multi-contrast approach with relevant MRI sequence and with a high
resolution whole brain exploration might improve the detection of CL in early MS.
Furthermore, MRI protocol allow us to estimate neuronal loss (T1 relaxation time), myelin and
iron content (QSM and T2* relaxation time) within and outside cortical lesions in GM.
The present study is an opportunity to assess cortical pathology in MS from the onset of the
disease, allowing to a better understanding of its origins and its impact and disease
severity. This study is a preliminary requirement to longitudinal studies to precisely depict
the kinetic of cortical lesion accumulation and the links with disease aggravation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
Not yet recruiting |
NCT06053749 -
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
|
||
Not yet recruiting |
NCT06450600 -
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
|
N/A | |
Recruiting |
NCT04926818 -
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
|
Phase 3 | |
Terminated |
NCT04203498 -
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
|
Phase 3 | |
Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT01804647 -
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
|
||
Terminated |
NCT04907305 -
Next-Gen MS: Feed-forward PRO Data for MS Research
|
||
Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
Completed |
NCT03135249 -
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 | |
Recruiting |
NCT05633875 -
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
|
||
Completed |
NCT02612935 -
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
|
N/A | |
Completed |
NCT02739542 -
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
|
Phase 4 | |
Completed |
NCT03177655 -
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT04777539 -
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
|
||
Recruiting |
NCT02352194 -
Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02308579 -
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
|
N/A | |
Withdrawn |
NCT01710228 -
Alternative Treatment Paradigm for Natalizumab Trial
|
Phase 2 |